Long-term use of nitroglycerin can deplete certain sulfur-containing molecules in the body that help activate the drug; giving N-acetylcysteine, a supplement that replenishes these molecules, can sometimes restore the drug's effectiveness.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A systematic review could determine whether N-acetylcysteine consistently prevents or reverses nitroglycerin tolerance across randomized trials and whether this effect is clinically meaningful.
A systematic review and meta-analysis of all randomized controlled trials evaluating N-acetylcysteine (oral or IV) for prevention or reversal of nitroglycerin tolerance in patients with angina, using standardized definitions of tolerance and outcomes including angina frequency, nitrate dose escalation, and hemodynamic response.
An RCT could determine whether N-acetylcysteine prevents the decline in mitochondrial aldehyde dehydrogenase activity and preserves nitroglycerin efficacy during chronic therapy.
A double-blind RCT of 80 patients with stable angina receiving daily nitroglycerin patches for 14 days, randomized to N-acetylcysteine (1200 mg/day) or placebo, with primary outcome being change in mitochondrial aldehyde dehydrogenase activity in leukocytes and secondary outcomes including angina episodes and nitrate consumption.
A prospective cohort could determine whether baseline thiol levels predict the development of nitroglycerin tolerance and whether N-acetylcysteine supplementation alters this trajectory.
A prospective cohort of 100 patients initiating chronic nitroglycerin therapy, with plasma and cellular thiol levels measured at baseline, week 2, and week 4, and randomized to receive N-acetylcysteine or no supplementation, with tolerance defined as doubling of nitroglycerin dose.
A case-control study could compare thiol levels in patients who developed tolerance versus those who did not, and whether N-acetylcysteine responders had lower baseline thiols.
A case-control study comparing plasma and leukocyte thiol levels in 40 patients who developed nitroglycerin tolerance (dose doubled) versus 40 matched controls who did not, and comparing thiol levels in the 20 responders to N-acetylcysteine versus 20 non-responders.
A cross-sectional study could correlate thiol levels with nitroglycerin efficacy in patients on chronic therapy.
A cross-sectional study measuring plasma and leukocyte glutathione and cysteine levels in 150 patients on chronic nitroglycerin therapy, correlating with self-reported efficacy and daily nitrate dose.